Skip to content
← All treatment topics

TREATMENT READING

Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

48 sections
  1. Treatment Option Overview for Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors
  2. Treatment of Circumscribed Astrocytic Gliomas, Pediatric-Type Diffuse Low-Grade Gliomas, and Glioneuronal/Neuronal Tumors
  3. Observation Without Intervention
  4. Surgery
  5. Adjuvant Therapy
  6. Observation after surgery
  7. Chemotherapy
  8. Radiation therapy
  9. Targeted therapy
  10. Treatment Options Under Clinical Evaluation
  11. Treatment of Progressive/Recurrent Circumscribed Astrocytic Gliomas, Pediatric-Type Diffuse Low-Grade Gliomas, and Glioneuronal/Neuronal Tumors
  12. Second Surgery
  13. Radiation Therapy
  14. Chemotherapy
  15. Targeted Therapy
  16. mTOR inhibitors
  17. VEGF inhibitors
  18. BRAF and MEK inhibitors
  19. Treatment Options Under Clinical Evaluation
  20. Treatment of Pediatric-Type Diffuse High-Grade Gliomas
  21. Surgery
  22. Adjuvant Therapy
  23. Radiation therapy
  24. Chemotherapy
  25. Targeted Therapy
  26. Immunotherapy
  27. Treatment Options Under Clinical Evaluation
  28. Treatment of Recurrent Pediatric-Type Diffuse High-Grade Gliomas
  29. Second Surgery
  30. Radiation Therapy
  31. Targeted Therapy
  32. Immunotherapy
  33. Treatment Options Under Clinical Evaluation
  34. Types of treatment for childhood glioma (including astrocytoma)
  35. Surgery
  36. Observation
  37. Chemotherapy
  38. Radiation therapy
  39. Targeted therapy
  40. Clinical trials
  41. Immunotherapy
  42. Treatment of newly diagnosed childhood low-grade glioma, astrocytoma, neuronal, and glioneuronal tumors
  43. Treatment of progressive or recurrent childhood low-grade glioma, astrocytoma, neuronal, or glioneuronal tumors
  44. Treatment of childhood high-grade gliomas
  45. Treatment of recurrent childhood high-grade gliomas
  46. Side effects from the tumor and treatment
  47. Treatment of newly diagnosed childhood low-grade glioma, astrocytoma, neuronal, and glioneuronal tumors
  48. Treatment of progressive or recurrent childhood low-grade glioma, astrocytoma, neuronal, or glioneuronal tumors

Health professional

Treatment Option Overview for Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors

Source: Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 14, 2025. Captured 2026-09-09.

Dramatic improvements in survival have been achieved for children and adolescents with cancer. Between 1975 and 2020, childhood cancer mortality decreased by more than 50%.[1] Many of the improvements in survival in childhood cancer have been made as a result of clinical trials that have attempted to improve on the best available, accepted therapy. Clinical trials in pediatrics are designed to compare new therapy with therapy that is currently accepted as standard. This comparison may be done in a randomized study of two treatment arms or by evaluating a single new treatment and comparing the results with previously obtained results that assessed an existing therapy. Because of the relative rarity of cancer in children, all patients with brain tumors should be considered for entry into a clinical trial. Information about ongoing National Cancer Institute (NCI)–supported clinical trials is available from the NCI website.

Sources: 1 · NCI website

To determine and implement optimal treatment, planning by a multidisciplinary team of cancer specialists who have experience treating childhood brain tumors is required. Irradiation of pediatric brain tumors is technically very demanding and should be carried out in centers that have experience in that area to ensure optimal results.

Long-term management of patients with brain tumors is complex and requires a multidisciplinary approach. For information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors, see Late Effects of Treatment for Childhood Cancer.

Sources: Late Effects of Treatment for Childhood Cancer

Table 3 describes the standard treatment options for childhood astrocytomas, other gliomas, and glioneuronal/neuronal tumors.

Sources: Table 3

Table 3. Standard Treatment Options for Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors
Treatment GroupStandard Treatment Options
Circumscribed astrocytic gliomas, pediatric-type diffuse low-grade gliomas, and glioneuronal/neuronal tumors:
Newly diagnosedObservation without intervention
Surgery
Adjuvant therapy:
—Observation after surgery (no adjuvant therapy)
—Chemotherapy
—Radiation therapy
—Targeted therapy
Progressive/recurrentSecond surgery
Radiation therapy
Chemotherapy
Targeted therapy
Pediatric-type diffuse high-grade gliomas:
Newly diagnosedSurgery
Adjuvant therapy:
—Radiation therapy
—Chemotherapy
Targeted therapy
Immunotherapy
RecurrentSecond surgery (not considered standard treatment)
Radiation therapy (not considered standard treatment)
Targeted therapy (not considered standard treatment)
Immunotherapy (not considered standard treatment)

Sources: Observation without intervention · Surgery · Adjuvant therapy · Observation after surgery · Chemotherapy · Radiation therapy · Targeted therapy · Second surgery · Radiation therapy · Chemotherapy · Targeted therapy · Surgery · Adjuvant therapy · Radiation therapy · Chemotherapy · Targeted therapy · Immunotherapy · Second surgery · Radiation therapy · Targeted therapy · Immunotherapy

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional

Treatment of Circumscribed Astrocytic Gliomas, Pediatric-Type Diffuse Low-Grade Gliomas, and Glioneuronal/Neuronal Tumors

Source: Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 14, 2025. Captured 2026-09-09.

To determine and implement optimal management, treatment is best guided by a multidisciplinary team of specialists experienced in treating pediatric patients with brain tumors.

For children with optic pathway gliomas, an important primary goal of treatment is preservation of visual function.[1]

Sources: 1

Standard treatment options for newly diagnosed circumscribed astrocytic gliomas, pediatric-type diffuse low-grade gliomas, and glioneuronal/neuronal tumors include the following:

Observation without intervention.

Sources: Observation without intervention

Surgery.

Sources: Surgery

Adjuvant therapy.

Sources: Adjuvant therapy

Adjuvant therapy.

Observation after surgery.

Sources: Observation after surgery

Chemotherapy.

Sources: Chemotherapy

Radiation therapy.

Sources: Radiation therapy

Targeted therapy.

Sources: Targeted therapy

Health professional · Treatment of Circumscribed Astrocytic Gliomas, Pediatric-Type Diffuse Low-Grade Gliomas, and Glioneuronal/Neuronal Tumors

Observation Without Intervention

Source: Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 14, 2025. Captured 2026-09-09.

Observation, without any intervention, is an option for patients with neurofibromatosis type 1 (NF1) or incidentally found, asymptomatic tumors.[2] Spontaneous regressions of optic pathway gliomas have been reported in children with and without NF1.[3,4]

Sources: 2 · 3 · 4

Health professional · Treatment of Circumscribed Astrocytic Gliomas, Pediatric-Type Diffuse Low-Grade Gliomas, and Glioneuronal/Neuronal Tumors

Surgery

Source: Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 14, 2025. Captured 2026-09-09.

Surgical resection is a primary treatment,[5,6] and surgical feasibility depends on tumor location. For example, safe surgical resection may not be feasible in many patients with optic pathway gliomas, because even a biopsy may present risks to the patient's vision. As a result, a diagnosis of an optic pathway glioma may rely on a compatible history and imaging findings alone. This is especially true in patients with NF1.[5] For other clinical presentations of an optic pathway tumor, particularly when the tumor is more infiltrative, a biopsy may be considered for molecular characterization of the tumor.

Sources: 5 · 6 · 5

For patients presenting with obstructive hydrocephalus, a shunt or other cerebrospinal fluid diversion procedure may also be needed.

Cerebellum: Complete or near-complete removal can be obtained in 90% to 95% of patients with pilocytic astrocytomas located in the cerebellum.[6]

Sources: 6

Optic nerve: For children with isolated optic nerve lesions and progressive symptoms, complete surgical resection, while curative, generally results in blindness in the affected eye. In the absence of retained vision in the affected eye, complete surgical resection may be considered when cosmesis related to proptosis is of concern.

Midline structures (hypothalamus, thalamus, and brain stem): Circumscribed astrocytic gliomas located in midline structures can sometimes be aggressively resected, with resultant long-term disease control.[3] Despite the increasing surgical accessibility of these tumors, such resection may result in significant neurological sequelae, especially in children younger than 2 years at diagnosis.[7][Level of evidence C1] For pediatric-type diffuse low-grade gliomas in deep-seated lesions, extensive surgical resection may not be appropriate and biopsy only should be considered.[8][Level of evidence C2] In general, for focal brain stem gliomas, particularly those arising in the pons and medulla, maximal safe surgical resection is attempted.[9] While a greater extent of resection is associated with a higher progression-free survival (PFS), this must be balanced with the risk of new postsurgical complications. In a series of 116 patients with low-grade gliomas of the brain stem, 100 patients had some surgical intervention. Twenty-seven patients underwent a biopsy, only one of whom had new postoperative deficits. Seventy-three patients underwent a complete or partial resection, and almost 30% of this group had significant postoperative complications, including respiratory insufficiency (five patients), cerebellar mutism (three patients), and cranial nerve palsies or paresis (15 patients).[10]

Sources: 3 · 7 · Level of evidence C1 · 8 · Level of evidence C2 · 9 · 10

Cerebrum: Hemispheric circumscribed astrocytic gliomas are often amenable to complete surgical resection.

Spine: Surgical resection of spinal tumors is generally attempted but it often cannot be completed. In a cohort of 128 patients with primary spinal cord low-grade gliomas, gross-total resection was achieved in a minority of the patients (24 of 128). For the entire cohort, long-term disease control was achieved in about 87% of patients, but subsequent treatment in the form of repeat resection, chemotherapy, and/or radiation therapy was frequently required. Notably, disease progression was common (51 of 128 patients), with late-progression events occurring often. Neurological sequelae and orthopedic complications were common.[11][Level of evidence C2]

Sources: 11 · Level of evidence C2

After resection, immediate (within 48 hours of resection per Children’s Oncology Group [COG] criteria) postoperative magnetic resonance imaging is obtained. Surveillance scans are then obtained periodically for completely resected tumors, although the value following the initial 3- to 6-month postoperative period is uncertain.[12]; [13][Level of evidence C2]

Sources: 12 · 13 · Level of evidence C2

Factors related to outcome for children with low-grade gliomas treated with surgery followed by observation were identified in a COG study that included 518 evaluable patients.[6] Overall outcome for the entire group was an 8-year PFS rate of 78% and an 8-year overall survival (OS) rate of 96%. The following factors were related to prognosis:[6]

Sources: 6 · 6

Tumor location: Children with cerebellar and cerebral tumors showed a higher PFS rate at 8 years compared with patients with midline and chiasmatic tumors (84% ± 1.9% vs. 51% ± 5.9%, respectively).

Histology: Approximately three-fourths of patients had pilocytic astrocytoma; PFS and OS were superior for these patients when compared with children with nonpilocytic tumors.

Extent of resection: Patients with gross-total resection had 8-year PFS rates exceeding 90% and OS rates of 99%. By comparison, approximately one-half of patients with any degree of residual tumor (as assessed by operative report and by postoperative imaging) showed disease progression by 8 years, although OS rates exceeded 90%.[6] A multivariate analysis examined 100 patients with confirmed diagnoses of World Health Organization (WHO) grade 2 diffuse gliomas treated in an International Society of Paediatric Oncology (SIOP) study. The extent of glioma resection had the greatest impact on event-free survival (EFS) rates. The 5-year EFS rates were 75% to 76% for patients who underwent a complete or subtotal resection. In comparison, 5-year EFS rates were 56% for patients who had a partial resection and 19% for patients who had a biopsy.[14][Level of evidence B4]The extent of resection necessary for cure is unknown because patients with microscopic and even gross residual tumor after surgery may experience long-term PFS without postoperative therapy.[5,6]

Sources: 6 · 14 · Level of evidence B4 · 5 · 6

Age: Younger children (age <5 years) showed higher rates of tumor progression but there was no significant age effect for OS in multivariate analysis. In a retrospective review of a different series of pediatric patients, children younger than 1 year with low-grade gliomas demonstrated an inferior PFS compared with children aged 1 year and older.[15]

Sources: 15

The long-term functional outcome of patients with cerebellar pilocytic astrocytomas is relatively favorable. Full-scale mean intelligence quotients (IQs) of patients with low-grade gliomas treated with surgery alone are close to the normative population. However, these patients may have long-term medical, psychological, and educational deficits.[16]; [17,18][Level of evidence C1]

Sources: 16 · 17 · 18 · Level of evidence C1

Health professional · Treatment of Circumscribed Astrocytic Gliomas, Pediatric-Type Diffuse Low-Grade Gliomas, and Glioneuronal/Neuronal Tumors

Adjuvant Therapy

Source: Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 14, 2025. Captured 2026-09-09.

Adjuvant therapy following complete resection is generally not required unless there is a subsequent recurrence of disease. Treatment options for patients with incompletely resected tumor must be individualized and may include one or more of the following:

Observation after surgery (no adjuvant therapy).

Sources: Observation after surgery

Chemotherapy.

Sources: Chemotherapy

Radiation therapy.

Sources: Radiation therapy

Targeted therapy (for subependymal giant cell astrocytomas).

Sources: Targeted therapy

Health professional · Treatment of Circumscribed Astrocytic Gliomas, Pediatric-Type Diffuse Low-Grade Gliomas, and Glioneuronal/Neuronal Tumors / Adjuvant Therapy

Observation after surgery

Source: Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 14, 2025. Captured 2026-09-09.

Patients whose tumors have been partially resected may be observed without further disease-directed treatment, particularly if the pace of tumor regrowth is anticipated to be very slow. Approximately 50% of patients with less-than-gross total resections have disease that does not progress in 5 to 8 years, supporting the observation strategy in selected patients.[6]

Sources: 6

A multi-institutional retrospective study of children with IDH-altered low-grade gliomas revealed that 39 of 45 patients (87%) were managed with observation after surgery, including 20 patients who underwent biopsy or subtotal resection only. For these 39 patients, the 5-year PFS rate was 42%, and the 10-year PFS rate was 0%, with a median PFS of 4.76 years. The extent of resection did not significantly impact survival.[19]

Sources: 19

Health professional · Treatment of Circumscribed Astrocytic Gliomas, Pediatric-Type Diffuse Low-Grade Gliomas, and Glioneuronal/Neuronal Tumors / Adjuvant Therapy

Chemotherapy

Source: Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 14, 2025. Captured 2026-09-09.

Given the long-term side effects associated with radiation therapy, chemotherapy is recommended as first-line therapy for most pediatric patients who require adjuvant therapy after surgery.

Chemotherapy may result in objective tumor shrinkage and help avoid, or at least delay, the need for radiation therapy in most patients.[20-22] Chemotherapy is also an option for adolescents with optic nerve pathway gliomas to delay or avoid radiation therapy.[23][Level of evidence C2] Chemotherapy has been shown to shrink tumors in children with hypothalamic gliomas and the diencephalic syndrome, resulting in weight gain in those who respond to treatment.[24]

Sources: 20 · 22 · 23 · Level of evidence C2 · 24

The most widely used regimens to treat tumor progression or symptomatic nonresectable, pediatric low-grade gliomas are the following:

Carboplatin with or without vincristine.[21,25,26]; [27][Level of evidence C2]

Sources: 21 · 25 · 26 · 27 · Level of evidence C2

Vinblastine.[28,29]

Sources: 28 · 29

A combination of thioguanine, procarbazine, lomustine, and vincristine (TPCV).[30]; [20][Level of evidence A1]

Sources: 30 · 20 · Level of evidence A1

The COG reported the results of a randomized phase III trial (COG-A9952) that treated children younger than 10 years with low-grade chiasmatic/hypothalamic gliomas without NF1 using one of two regimens: carboplatin and vincristine (CV) or TPCV. The 5-year EFS rate was 39% (± 4%) for patients who received the CV regimen and 52% (± 5%) for patients who received the TPCV regimen. Toxicity rates between the two regimens were relatively comparable.[20] In the same study, children with NF1 were nonrandomly assigned to receive treatment with CV. The 5-year EFS rate for children with NF1 was markedly better, at 69% (± 4%), than it was for children without NF1 who received CV. In multivariate analysis, NF1 was an independent predictor of better EFS but not OS.[31] In a separate study that included 100 patients with WHO grade 2 diffuse gliomas, a subset of patients (n = 16) were treated with CV, and some patients also received etoposide. This subset of patients had a 5-year PFS rate of 38% when patients with histone H3 variants were excluded.[14][Level of evidence B4]

Sources: COG-A9952 · 20 · 31 · 14 · Level of evidence B4

Other chemotherapy approaches that have been employed to treat children with progressive or symptomatic nonresectable, low-grade astrocytomas include the following:

Multiagent, platinum-based regimens.[21,22,32]; [33][Level of evidence B4]; [34][Level of evidence C1] Reported 5-year PFS rates have ranged from approximately 35% to 60% for children who received platinum-based chemotherapy for optic pathway gliomas,[21,22] but most patients ultimately require further treatment. This is particularly true for children who initially present with hypothalamic/chiasmatic gliomas that have neuraxis dissemination.[35][Level of evidence C2]

Sources: 21 · 22 · 32 · 33 · Level of evidence B4 · 34 · Level of evidence C1 · 21 · 22 · 35 · Level of evidence C2

Temozolomide.[36,37]

Sources: 36 · 37

Among children who received chemotherapy for optic pathway gliomas, those without NF1 had higher rates of disease progression than those with NF1, and infants had higher rates of disease progression than children older than 1 year.[21,22,29] Visual status (including acuity and field) is an important measure of outcome and response to treatment. Vision function can be impaired; it is variable even in patients with radiographic responses and is often less than optimal. More than one-third of patients successfully treated with chemotherapy have poor vision in one or both eyes, and some patients lose vision despite radiographic evidence of tumor control (response or stability). In most series, children with sporadic visual pathway gliomas have poorer visual outcomes than do children with NF1.[29]; [38,39][Level of evidence C1] Better initial visual acuity, older age, and absence of postchiasmatic involvement are associated with improved or stable vision after chemotherapy.[40,41]

Sources: 21 · 22 · 29 · 29 · 38 · 39 · Level of evidence C1 · 40 · 41

Health professional · Treatment of Circumscribed Astrocytic Gliomas, Pediatric-Type Diffuse Low-Grade Gliomas, and Glioneuronal/Neuronal Tumors / Adjuvant Therapy

Radiation therapy

Source: Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 14, 2025. Captured 2026-09-09.

Radiation therapy is usually reserved for patients with disease that does not durably respond to chemotherapy.[21,22,42,43]

Sources: 21 · 22 · 42 · 43

For children with low-grade gliomas for whom radiation therapy is indicated, approaches that contour the radiation distribution to the tumor and avoid normal brain tissue (3-D conformal radiation therapy, intensity-modulated radiation therapy (IMRT), stereotactic radiation therapy, and proton radiation therapy [charged-particle radiation therapy]) can reduce the acute and long-term toxicities associated with these modalities.[44,45]; [46][Level of evidence C2] Radiation doses of 54 Gy in 1.8 Gy fractions are typically used.[47,48] In a prospective study of 174 patients treated with proton therapy, the 5-year actuarial rate of local control was 85% (95% confidence interval [CI], 78%–90%), the PFS rate was 84% (95% CI, 77%–89%), and the OS rate was 92% (95% CI, 85%–95%). Brain stem and spinal cord tumor locations and a dose of 54 Gy relative biological effectiveness (RBE) or less were associated with inferior local control (P < .01 for both).[49] In a separate study that included 100 patients with WHO grade 2 diffuse gliomas, a subset of patients (n = 16) were treated with radiation therapy. These patients had a 5-year PFS rate of 74% when patients with histone H3 variants were excluded.[14][Level of evidence B4]

Sources: 3-D conformal radiation therapy · intensity-modulated radiation therapy (IMRT) · stereotactic radiation therapy · proton radiation therapy [charged-particle radiation therapy] · 44 · 45 · 46 · Level of evidence C2 · 47 · 48 · 49 · 14 · Level of evidence B4

Subsequent to radiation therapy administration, care must be taken to distinguish radiation-induced imaging changes, termed pseudoprogression or spurious progression,[50] from disease progression. The peak time to radiation therapy–induced imaging changes, often presenting as an apparent enlargement of the irradiated mass, is 4 to 6 months, but they can manifest even later.[51-54]; [55,56][Level of evidence B4]; [8,57,58][Level of evidence C2] In a report of 83 patients with low-grade astrocytomas, pseudoprogression was more common after radiation doses of higher than 50.4 Gy (RBE) (hazard ratio [HR], 2.61; P = .16). Pseudoprogression was also more common after proton radiation therapy than after photon IMRT (HR, 2.15; P = .048), presumably because of increased effects on the vasculature. Patients with pilocytic histology had lower rates of pseudoprogression than those with nonpilocytic low-grade gliomas (HR, 0.47; P = .037). There was no association with overall disease control.[50]

Sources: 50 · 51 · 54 · 55 · 56 · Level of evidence B4 · 8 · 57 · 58 · Level of evidence C2 · 50

A report from the SIOP-LGG 2004 (NCT00276640) study and LGG-registry cohorts evaluated the following radiological criteria for pseudoprogression:[59]

Sources: SIOP-LGG 2004 (NCT00276640) · 59

Increasing total tumor–associated T2 lesion.

Increasing focal tumor–associated T2 lesion.

Increasing contrast-enhancing tumor in the first 24 months after radiation therapy.

The following results were observed:

Definite pseudoprogression was radiologically determined in 54 of 136 patients (39.7%) without differences in frequency between radiation therapy modalities: iodine-interstitial radiation therapy (22 of 48 patients) versus photon radiation therapy (24 of 54 patients) versus proton-beam radiation therapy (11 of 20 patients) (P = .780).

Definite pseudoprogression occurred at median 6.3 months (iodine-interstitial radiation therapy, 7.2 months; photon radiation therapy, 4.4 months; proton-beam radiation therapy, 6.5 months) after radiation therapy initiation and persisted for a median of 7.2 months (iodine-interstitial radiation therapy, 8.5 months; photon radiation therapy, 7 months; proton-beam radiation therapy, 7.4 months).

Appearance of necrosis within the focal tumor–associated T2 lesion proved to be a relevant predictor of definite pseudoprogression (P < .001).

Radiation therapy results in long-term radiographic disease control for most children with chiasmatic and posterior pathway chiasmatic gliomas. However, despite radiological control, visual outcomes are variable.

A study from St. Jude Children’s Research Hospital reported on long-term visual acuity outcomes after radiation therapy. For the worse eye, the 5-year cumulative incidence of visual acuity decline was 17.9% and improvement was 13.5%. For the better eye, the 5-year cumulative incidence of visual acuity decline was 11.5% and improvement was 10.6%. After radiation therapy, most patients had stabilization of their vision. Visual change after radiation therapy was most likely to occur within 2 years, supporting the importance of visual assessments during this period.[60]

Sources: 60

Another study of 38 patients (mean age, 3 years; median follow-up, 8.5 years) with optic pathway gliomas treated between 2000 and 2018 complemented the previous data on preservation of long-term visual acuity. For patients treated with early radiation therapy (either up-front or as first salvage), blindness-free survival rates were 100% at 5 and 8 years. In comparison, blindness-free survival rates were 81% at 5 years and 60% at 8 years for patients treated primarily with chemotherapy.[61]

Sources: 61

Other sequelae include intellectual and endocrinologic deterioration, cerebrovascular damage, late death, and possibly an increased risk of secondary tumors.[62-64]; [56][Level of evidence B4] A population-based study identified radiation therapy as the most significant risk factor associated with late mortality, although the patients who required radiation therapy may have reflected a higher-risk population.[64]

Sources: 62 · 64 · 56 · Level of evidence B4 · 64

The management of unresectable circumscribed astrocytic gliomas, pediatric-type diffuse low-grade gliomas, glioneuronal tumors, and neuronal tumors is controversial. To identify negative prognostic features in patients treated with radiation therapy, the St. Jude Children’s Research Hospital assessed 150 children (median age, 8 years; range, 1.2–20 years) who received radiation therapy and were monitored for a median of 11.4 years (range, 0.24–29.4 years). Recursive positioning analysis yielded low-risk and high-risk prognostic groups. The 10-year OS rate was 95.6% for patients in the low-risk group, versus 76.4% for patients in the high-risk group. Low-risk tumors included pilocytic astrocytoma/ganglioglioma located outside of the midbrain/thalamus, while high-risk tumors included diffuse astrocytoma or those located in the midbrain/thalamus. Within the high-risk group of patients, delayed radiation therapy (defined as after at least one line of chemotherapy) was associated with a decrement in OS.[65]

Sources: 65

Children with NF1 may be at higher risk of radiation-associated secondary tumors and morbidity resulting from vascular changes. Radiation therapy is used as a last resort in these patients, given the heightened risk of inducing neurological toxic effects and second malignancy.[66]

Sources: 66

Health professional · Treatment of Circumscribed Astrocytic Gliomas, Pediatric-Type Diffuse Low-Grade Gliomas, and Glioneuronal/Neuronal Tumors / Adjuvant Therapy

Targeted therapy

Source: Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 14, 2025. Captured 2026-09-09.

The U.S. Food and Drug Administration (FDA) approved the combination of trametinib (MEK inhibitor) plus dabrafenib (BRAF inhibitor) for the treatment of pediatric patients aged 1 year and older with low-grade gliomas and a BRAF V600E variant who require systemic therapy. The approval was based on a randomized clinical trial that compared the dabrafenib-plus-trametinib combination with the carboplatin-plus-vincristine combination. The median age of enrolled patients was 9.5 years, and the most common histological subtypes were ganglioglioma (about 25%) and pilocytic astrocytoma (about 30%). Patients were randomly assigned in a 2-to-1 ratio, with 73 receiving dabrafenib plus trametinib and 37 receiving carboplatin plus vincristine. Patients received dabrafenib and trametinib until loss of clinical benefit or until unacceptable toxicity, and the carboplatin-plus-vincristine combination was given as a 10-week induction course, followed by eight 6-week cycles of therapy.[67]

Sources: 67

The objective response rate was assessed by independent review using Response Assessment in Neuro-Oncology (RANO) 2017 response criteria for low-grade glioma that employ T2-fluid attenuated inversion recovery (FLAIR) rather than contrast enhancement.

Patients randomly assigned to dabrafenib plus trametinib had a significantly higher objective response rate compared with patients who received carboplatin plus vincristine (47% vs. 11%). An additional 41% of patients in each treatment group had stable disease.

Patients randomly assigned to dabrafenib plus trametinib had a significantly longer PFS compared with patients who received carboplatin plus vincristine (20.1 months vs. 7.4 months).

Grade 3 or higher adverse events were more common in patients who received carboplatin plus vincristine compared with patients who received dabrafenib plus trametinib (94% vs. 47%).

IDH inhibitors are being studied for the treatment of patients with IDH-altered low-grade and high-grade gliomas. One agent, vorasidenib, has shown preliminary evidence of activity in delaying the time to progression when compared with placebo in newly diagnosed adults with IDH1- or IDH2-altered low-grade gliomas.[68] The FDA approved vorasidenib for adult and pediatric patients aged 12 years and older with grade 2 astrocytomas or oligodendrogliomas and a susceptible IDH1 or IDH2 variant after surgery, which includes biopsy, subtotal resection, or gross-total resection.

Sources: 68

For children with tuberous sclerosis (TS) and symptomatic subependymal giant cell astrocytomas (SEGAs), agents that inhibit mammalian target of rapamycin (mTOR) (e.g., everolimus and sirolimus) have been studied.

Evidence (treatment of SEGA with an mTOR inhibitor):

Small series have shown significant reductions in the size of these tumors after administration of everolimus or sirolimus, often eliminating the need for surgery.[69]; [70][Level of evidence B4]; [71][Level of evidence C3]; [72][Level of evidence C1]

Sources: 69 · 70 · Level of evidence B4 · 71 · Level of evidence C3 · 72 · Level of evidence C1

A multicenter, phase III, placebo-controlled trial of 117 patients confirmed these earlier findings.[73][Level of evidence B3]

Sources: 73 · Level of evidence B3

A multicenter, phase III, placebo-controlled trial of 117 patients confirmed these earlier findings.[73][Level of evidence B3]

Thirty-five percent of the patients in the everolimus group had at least a 50% reduction in the size of the SEGA, versus no reduction in the placebo group.

In a study of patients who were treated with everolimus for 5 years, the following results were observed:[74]

Sources: 74

In a study of patients who were treated with everolimus for 5 years, the following results were observed:[74]

A reduction in the size of the mass was observed in about 50% of patients; in many cases, the reduction was sustained.

These patients also had a reduction in seizure frequency.

Health professional · Treatment of Circumscribed Astrocytic Gliomas, Pediatric-Type Diffuse Low-Grade Gliomas, and Glioneuronal/Neuronal Tumors

Treatment Options Under Clinical Evaluation

Source: Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 14, 2025. Captured 2026-09-09.

Early-phase therapeutic trials may be available for selected patients. These trials may be available via the COG, the Pediatric Brain Tumor Consortium, or other entities. Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: COG · Pediatric Brain Tumor Consortium · NCI website · ClinicalTrials.gov website

The following are examples of national and/or institutional clinical trials that are currently being conducted:

ACNS1831 (NCT03871257) (A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With NF1 and Low-Grade Glioma): This phase III trial investigates the use of selumetinib compared with the standard treatment of CV for treating patients with NF1-associated low-grade gliomas, and improving vision in patients with low-grade gliomas of the optic pathway (vision nerves).

Sources: ACNS1831 (NCT03871257

ACNS1833 (NCT04166409) (A Study of the Drugs Selumetinib Versus Carboplatin and Vincristine in Patients With Low-Grade Glioma): This phase III trial compares the effect of selumetinib with the standard of care treatment using carboplatin and vincristine in treating patients with newly diagnosed or previously untreated low-grade glioma that does not have a BRAF V600E variant and is not associated with systemic NF1.

Sources: ACNS1833 (NCT04166409)

Health professional

Treatment of Progressive/Recurrent Circumscribed Astrocytic Gliomas, Pediatric-Type Diffuse Low-Grade Gliomas, and Glioneuronal/Neuronal Tumors

Source: Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 14, 2025. Captured 2026-09-09.

There is no single standard treatment option for progressive/recurrent circumscribed astrocytic gliomas, pediatric-type diffuse low-grade gliomas, glioneuronal tumors, and neuronal tumors. To determine and implement optimal management, treatment is best guided by a multidisciplinary team of specialists with experience treating pediatric patients with brain tumors.

An individual plan needs to be tailored based on the following:

Patient age.

Tumor location.

Pathology, including genomic findings.

Relevant germline findings/inheritable tumor predispositions.

Prior treatment.

Recurrent disease is usually at the primary tumor site, although multifocal or widely disseminated disease to other intracranial sites and to the spinal leptomeninges has been documented.[1,2] Most recurrences are of the same tumor entity; however, transformation into a higher grade tumor is possible and associated with the molecular profile.[3] Surveillance imaging will frequently identify asymptomatic recurrences.[4] At the time of recurrence, a complete evaluation to determine the extent of the relapse is indicated.

Sources: 1 · 2 · 3 · 4

Tumor sample sequencing was done in pediatric (n = 48) and young adult patients (n = 6) with recurrent or refractory low-grade gliomas who were enrolled in the National Cancer Institute (NCI)–Children's Oncology Group (COG) Pediatric MATCH trial. The test revealed genomic alterations that were considered actionable for treatment on MATCH study arms in 39 of 54 tumors (72.2%).[5] Alterations in MAPK pathway genes (most commonly BRAF and NF1) were detected in 26 of 54 tumors (48.1%). FGFR1 variants (n = 11) or fusions (n = 1) were identified in 12 of 54 tumors (22.2%).

Sources: 5

Treatment options for progressive/recurrent circumscribed astrocytic gliomas, pediatric-type diffuse low-grade gliomas, and glioneuronal/neuronal tumors include the following:

Second surgery.

Sources: Second surgery

Radiation therapy.

Sources: Radiation therapy

Chemotherapy.

Sources: Chemotherapy

Targeted therapy.

Sources: Targeted therapy

Health professional · Treatment of Progressive/Recurrent Circumscribed Astrocytic Gliomas, Pediatric-Type Diffuse Low-Grade Gliomas, and Glioneuronal/Neuronal Tumors

Second Surgery

Source: Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 14, 2025. Captured 2026-09-09.

Consideration of surgical intervention must be individualized based on the following:

Initial tumor type.

Length of time between initial treatment and tumor recurrence/progression.

Clinical picture.

Utility of second surgery is impacted by site of recurrence and the probability of obtaining a near-total resection/gross-total resection without significant neurological injury.[6]

Sources: 6

Health professional · Treatment of Progressive/Recurrent Circumscribed Astrocytic Gliomas, Pediatric-Type Diffuse Low-Grade Gliomas, and Glioneuronal/Neuronal Tumors

Radiation Therapy

Source: Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 14, 2025. Captured 2026-09-09.

The rationale for the use of radiation therapy is essentially the same for first-line therapy or at the time of recurrence. For more information, see the Radiation therapy section. If the child has never received radiation therapy, local radiation therapy may be a treatment option, although chemotherapy in lieu of radiation should be considered, depending on the child's age and the extent and location of the tumor.[7][Level of evidence C1]; [8][Level of evidence C2]

Sources: Radiation therapy · 7 · Level of evidence C1 · 8 · Level of evidence C2

For children with low-grade gliomas for whom radiation therapy is indicated, conformal radiation therapy (including proton-beam therapy) approaches appear effective and offer the potential for reducing the acute and long-term toxicities associated with this modality.[9-12]

Sources: conformal radiation therapy · 9 · 12

Health professional · Treatment of Progressive/Recurrent Circumscribed Astrocytic Gliomas, Pediatric-Type Diffuse Low-Grade Gliomas, and Glioneuronal/Neuronal Tumors

Chemotherapy

Source: Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 14, 2025. Captured 2026-09-09.

If there is recurrence or progression at an unresectable site, chemotherapy should be considered.

Chemotherapy may result in relatively long-term disease control.[13,14] The choice of regimen depends on the type of and response to prior chemotherapy. Numerous options can be considered, most commonly including carboplatin with or without vincristine (CV); thioguanine, procarbazine, lomustine, and vincristine (TPCV); or vinblastine alone; temozolomide alone; temozolomide in combination with carboplatin and vincristine; irinotecan and bevacizumab; or lenalidomide.[13-17] When a therapeutically actionable molecular alteration is identified in the tumor, molecular targeted therapy is increasingly being used as second-line therapy.

Sources: 13 · 14 · 13 · 17

Health professional · Treatment of Progressive/Recurrent Circumscribed Astrocytic Gliomas, Pediatric-Type Diffuse Low-Grade Gliomas, and Glioneuronal/Neuronal Tumors

Targeted Therapy

Source: Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 14, 2025. Captured 2026-09-09.

Health professional · Treatment of Progressive/Recurrent Circumscribed Astrocytic Gliomas, Pediatric-Type Diffuse Low-Grade Gliomas, and Glioneuronal/Neuronal Tumors / Targeted Therapy

mTOR inhibitors

Source: Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 14, 2025. Captured 2026-09-09.

For children with tuberous sclerosis (TS) and symptomatic subependymal giant cell astrocytomas (SEGAs) or low-grade gliomas,[18] mammalian target of rapamycin (mTOR) inhibitors (e.g., everolimus and sirolimus) have been studied.

Sources: 18

Evidence (mTOR inhibitors):

Small series have shown significant reductions in the size of these tumors after administration of everolimus or sirolimus, often eliminating the need for surgery.[19]; [20][Level of evidence B4]; [21][Level of evidence C3]; [22][Level of evidence C1]

Sources: 19 · 20 · Level of evidence B4 · 21 · Level of evidence C3 · 22 · Level of evidence C1

A multicenter, phase III, placebo-controlled trial of 117 patients confirmed these earlier findings.[23][Level of evidence B3]

Sources: 23 · Level of evidence B3

A multicenter, phase III, placebo-controlled trial of 117 patients confirmed these earlier findings.[23][Level of evidence B3]

Thirty-five percent of the patients in the everolimus group had at least a 50% reduction in the size of the SEGA, versus no reduction in the placebo group.

In a study of patients who were treated with everolimus for 5 years, the following results were observed:[24]

Sources: 24

In a study of patients who were treated with everolimus for 5 years, the following results were observed:[24]

A reduction in the size of the mass was observed in about 50% of patients; in many cases, the reduction was sustained.

These patients also had a reduction in seizure frequency.

In a series of 23 patients with recurrent low-grade gliomas who were treated with everolimus, the following was observed:[25]

Sources: 25

In a series of 23 patients with recurrent low-grade gliomas who were treated with everolimus, the following was observed:[25]

Everolimus demonstrated modest activity, with a 2-year progression-free survival (PFS) rate of 39% and an overall survival rate of 93%.

A companion study completed by the Neurofibromatosis Clinical Trials Consortium evaluated 23 children with neurofibromatosis type 1 (NF1) and progressive low-grade gliomas who were treated with everolimus.[26]

Sources: 26

A companion study completed by the Neurofibromatosis Clinical Trials Consortium evaluated 23 children with neurofibromatosis type 1 (NF1) and progressive low-grade gliomas who were treated with everolimus.[26]

Of the 22 evaluable patients, 15 demonstrated either a partial response or tumor stabilization, 10 of whom remained free of progression for a median follow-up of 33 months.

Health professional · Treatment of Progressive/Recurrent Circumscribed Astrocytic Gliomas, Pediatric-Type Diffuse Low-Grade Gliomas, and Glioneuronal/Neuronal Tumors / Targeted Therapy

VEGF inhibitors

Source: Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 14, 2025. Captured 2026-09-09.

Antitumor activity has also been observed for bevacizumab given in combination with irinotecan, which, in some cases, also results in clinical or visual improvement.[27]

Sources: 27

Evidence (targeted therapy [bevacizumab]):

In a phase II study of bevacizumab plus irinotecan for children with recurrent low-grade gliomas, the following results were observed:[28]

Sources: 28

In a phase II study of bevacizumab plus irinotecan for children with recurrent low-grade gliomas, the following results were observed:[28]

Sustained partial responses were observed in only two patients (5.7%).

The 6-month PFS rate was 85.4% (standard error [SE] ± 5.96%).

The 2-year PFS rate was 47.8% (SE ± 9.27%).

A pilot study of 14 patients with recurrent low-grade gliomas also evaluated bevacizumab-based therapies and observed the following:[29][Level of evidence C2]; [30][Level of evidence C3]

Sources: 29 · Level of evidence C2 · 30 · Level of evidence C3

A pilot study of 14 patients with recurrent low-grade gliomas also evaluated bevacizumab-based therapies and observed the following:[29][Level of evidence C2]; [30][Level of evidence C3]

Objective responses were seen in 12 patients (86%).

No patients progressed on therapy (median treatment duration, 12 months), but 13 of 14 progressed after stopping bevacizumab at a median of 5 months.

A retrospective pooled analysis included 88 children with low-grade gliomas who received bevacizumab-based treatment along with additional therapy.[31]

Sources: 31

A retrospective pooled analysis included 88 children with low-grade gliomas who received bevacizumab-based treatment along with additional therapy.[31]

A partial response was observed in 40% of patients, and stable disease was seen in 49% of patients.

Sixty-five percent of the patients progressed at a median of 8 months after discontinuation of bevacizumab-based treatment. The radiographic PFS rate was 29% at 3 years.

Stability in visual function was seen in 49% of patients, and visual function improved in 29% of patients. Despite radiographic progression in many patients, the 3-year visual-PFS rate was 53%.

Bevacizumab has also been employed for children with low-grade gliomas and symptomatic radiation-induced tumor enlargement.[32,33]

Sources: 32 · 33

Bevacizumab has also been employed for children with low-grade gliomas and symptomatic radiation-induced tumor enlargement.[32,33]

Treatment with bevacizumab produced imaging improvement (five of five patients) and allowed weaning off steroids (four of four patients).

Health professional · Treatment of Progressive/Recurrent Circumscribed Astrocytic Gliomas, Pediatric-Type Diffuse Low-Grade Gliomas, and Glioneuronal/Neuronal Tumors / Targeted Therapy

BRAF and MEK inhibitors

Source: Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 14, 2025. Captured 2026-09-09.

With the identification of BRAF variants driving a significant proportion of low-grade gliomas, inhibition of various elements of this molecular pathway (e.g., MEK and BRAF) are actively being tested in ongoing clinical trials, with early reports suggesting substantial activity. While first-generation BRAF inhibitors like vemurafenib and dabrafenib are active against tumors with BRAF V600E variants, they are contraindicated for tumors with BRAF gene fusions because of the potential for paradoxical activation of the MAPK pathway.[34,35] As described below, the U.S. Food and Drug Administration (FDA) approved the dabrafenib-plus-trametinib combination for use in pediatric patients aged 1 year and older with relapsed or refractory low-grade gliomas with BRAF V600E variants.

Sources: 34 · 35

For patients whose tumors have BRAF V600E variants, the focus of clinical research efforts is on the evaluation of BRAF inhibitors in combination with MEK inhibitors. Such combinations are approved for the treatment of adult cancers with BRAF V600E variants and are more effective than either BRAF inhibitors or MEK inhibitors used as single agents.[36]

Sources: 36

For patients whose tumors have BRAF V600E variants, the focus of clinical research efforts is on the evaluation of BRAF inhibitors in combination with MEK inhibitors. Such combinations are approved for the treatment of adult cancers with BRAF V600E variants and are more effective than either BRAF inhibitors or MEK inhibitors used as single agents.[36]

Results on the use of the BRAF V600E inhibitor dabrafenib demonstrated a 44% overall response rate (1 complete response and 13 partial responses) by central review in children with BRAF V600 variants and relapsed or refractory low-grade gliomas. The median duration of response was 26 months. The disease control rate (complete response plus partial response plus stable disease) was 78%. The therapy was well tolerated, although 91% of patients experienced side effects such as fatigue (34%), rash (31%), and pyrexia (28%). Nine of 32 patients had grade 3 to grade 4 toxicities, 10 patients required dose modifications, and 2 patients discontinued treatment, including 1 child who had disseminated intravascular coagulation with hypertension. In this pediatric study, no cases of squamous cell carcinoma of the skin or keratoacanthoma were encountered.[37]

Sources: 37

A phase I/II study of trametinib as a single agent for patients with BRAF V600E variants and low-grade gliomas enrolled 13 pediatric patients. The objective response rate for these 13 patients was assessed by independent review using Response Assessment in Neuro-Oncology (RANO) 2017 response criteria for low-grade gliomas that employ T2-fluid attenuated inversion recovery (FLAIR) rather than contrast enhancement.[38]

Sources: 38

For patients whose tumors have BRAF V600E variants, the focus of clinical research efforts is on the evaluation of BRAF inhibitors in combination with MEK inhibitors. Such combinations are approved for the treatment of adult cancers with BRAF V600E variants and are more effective than either BRAF inhibitors or MEK inhibitors used as single agents.[36] › A phase I/II study of trametinib as a single agent for patients with BRAF V600E variants and low-grade gliomas enrolled 13 pediatric patients. The objective response rate for these 13 patients was assessed by independent review using Response Assessment in Neuro-Oncology (RANO) 2017 response criteria for low-grade gliomas that employ T2-fluid attenuated inversion recovery (FLAIR) rather than contrast enhancement.[38]

Two of 13 patients (15%) achieved partial responses, and 6 patients (46%) had stable disease.

The 24-month PFS rate was 50%.

For patients whose tumors have BRAF V600E variants, the focus of clinical research efforts is on the evaluation of BRAF inhibitors in combination with MEK inhibitors. Such combinations are approved for the treatment of adult cancers with BRAF V600E variants and are more effective than either BRAF inhibitors or MEK inhibitors used as single agents.[36]

A phase I/II study that evaluated the combination of dabrafenib and trametinib enrolled 34 patients with BRAF V600E variants and low-grade gliomas and 2 patients with BRAF V600E variants and high-grade gliomas. The objective response rate for these 36 patients was assessed by independent review using RANO 2017 response criteria for low-grade glioma that employ T2-FLAIR rather than contrast enhancement.[38]

Sources: 38

For patients whose tumors have BRAF V600E variants, the focus of clinical research efforts is on the evaluation of BRAF inhibitors in combination with MEK inhibitors. Such combinations are approved for the treatment of adult cancers with BRAF V600E variants and are more effective than either BRAF inhibitors or MEK inhibitors used as single agents.[36] › A phase I/II study that evaluated the combination of dabrafenib and trametinib enrolled 34 patients with BRAF V600E variants and low-grade gliomas and 2 patients with BRAF V600E variants and high-grade gliomas. The objective response rate for these 36 patients was assessed by independent review using RANO 2017 response criteria for low-grade glioma that employ T2-FLAIR rather than contrast enhancement.[38]

Nine of 36 patients (25%) achieved partial responses, and 23 patients (64%) had stable disease.

The 24-month PFS rate was 80%.

The most common treatment-related adverse events in the dabrafenib-plus-trametinib group were pyrexia (50%) and dry skin (42%). Adverse events leading to discontinuation of therapy occurred in 22% of patients, a lower rate than observed for patients who received single-agent trametinib (54%).

The FDA approved the trametinib-plus-dabrafenib combination for adult and pediatric patients aged 1 year and older with unresectable or metastatic solid tumors with BRAF V600E variants who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication includes pediatric patients aged 1 year and older with BRAF V600E variants and low-grade gliomas.

The MEK inhibitor selumetinib has been studied in a phase I/II clinical trial for children with low-grade gliomas (PBTC-029 [NCT01089101]). The most common toxicities across all strata were grade 1 and grade 2 CPK elevation, diarrhea, hypoalbuminemia, elevated aspartate aminotransferase (AST), and rash. Rare grade 3 and grade 4 toxicities included elevated CPK, rash, neutropenia, emesis, and paronychia.

Sources: PBTC-029 [NCT01089101]

The MEK inhibitor selumetinib has been studied in a phase I/II clinical trial for children with low-grade gliomas (PBTC-029 [NCT01089101]). The most common toxicities across all strata were grade 1 and grade 2 CPK elevation, diarrhea, hypoalbuminemia, elevated aspartate aminotransferase (AST), and rash. Rare grade 3 and grade 4 toxicities included elevated CPK, rash, neutropenia, emesis, and paronychia.

The phase I component of the PBTC-029 trial showed the following results:[39]

Sources: 39

The MEK inhibitor selumetinib has been studied in a phase I/II clinical trial for children with low-grade gliomas (PBTC-029 [NCT01089101]). The most common toxicities across all strata were grade 1 and grade 2 CPK elevation, diarrhea, hypoalbuminemia, elevated aspartate aminotransferase (AST), and rash. Rare grade 3 and grade 4 toxicities included elevated CPK, rash, neutropenia, emesis, and paronychia. › The phase I component of the PBTC-029 trial showed the following results:[39]

Selumetinib was tolerated at a daily dose of 25 mg/m2.

The most common adverse events leading to patient discontinuation of treatment were rash, paronychia, and asymptomatic creatine phosphokinase (CPK) elevation.

The MEK inhibitor selumetinib has been studied in a phase I/II clinical trial for children with low-grade gliomas (PBTC-029 [NCT01089101]). The most common toxicities across all strata were grade 1 and grade 2 CPK elevation, diarrhea, hypoalbuminemia, elevated aspartate aminotransferase (AST), and rash. Rare grade 3 and grade 4 toxicities included elevated CPK, rash, neutropenia, emesis, and paronychia.

Stratum 1 of the phase II component of this trial was for patients with BRAF genomic alterations.[40]

Sources: 40

The MEK inhibitor selumetinib has been studied in a phase I/II clinical trial for children with low-grade gliomas (PBTC-029 [NCT01089101]). The most common toxicities across all strata were grade 1 and grade 2 CPK elevation, diarrhea, hypoalbuminemia, elevated aspartate aminotransferase (AST), and rash. Rare grade 3 and grade 4 toxicities included elevated CPK, rash, neutropenia, emesis, and paronychia. › Stratum 1 of the phase II component of this trial was for patients with BRAF genomic alterations.[40]

Nine of 25 patients (36%) achieved a partial response, with responses occurring for both BRAF V600E patients and for patients with BRAF gene fusions.

The 2-year PFS rate was 70% for stratum 1 patients.

The MEK inhibitor selumetinib has been studied in a phase I/II clinical trial for children with low-grade gliomas (PBTC-029 [NCT01089101]). The most common toxicities across all strata were grade 1 and grade 2 CPK elevation, diarrhea, hypoalbuminemia, elevated aspartate aminotransferase (AST), and rash. Rare grade 3 and grade 4 toxicities included elevated CPK, rash, neutropenia, emesis, and paronychia.

Stratum 3 of the phase II component of this trial was for patients with NF1-associated low-grade gliomas.[40]

Sources: 40

The MEK inhibitor selumetinib has been studied in a phase I/II clinical trial for children with low-grade gliomas (PBTC-029 [NCT01089101]). The most common toxicities across all strata were grade 1 and grade 2 CPK elevation, diarrhea, hypoalbuminemia, elevated aspartate aminotransferase (AST), and rash. Rare grade 3 and grade 4 toxicities included elevated CPK, rash, neutropenia, emesis, and paronychia. › Stratum 3 of the phase II component of this trial was for patients with NF1-associated low-grade gliomas.[40]

The 2-year event-free survival rate for this group was 96%.

10 of 25 patients (40%) achieved partial responses.

The MEK inhibitor selumetinib has been studied in a phase I/II clinical trial for children with low-grade gliomas (PBTC-029 [NCT01089101]). The most common toxicities across all strata were grade 1 and grade 2 CPK elevation, diarrhea, hypoalbuminemia, elevated aspartate aminotransferase (AST), and rash. Rare grade 3 and grade 4 toxicities included elevated CPK, rash, neutropenia, emesis, and paronychia.

Stratum 4 of the phase II component of this trial was for patients with recurrent optic pathway and hypothalamic low-grade gliomas.[41]

Sources: 41

The MEK inhibitor selumetinib has been studied in a phase I/II clinical trial for children with low-grade gliomas (PBTC-029 [NCT01089101]). The most common toxicities across all strata were grade 1 and grade 2 CPK elevation, diarrhea, hypoalbuminemia, elevated aspartate aminotransferase (AST), and rash. Rare grade 3 and grade 4 toxicities included elevated CPK, rash, neutropenia, emesis, and paronychia. › Stratum 4 of the phase II component of this trial was for patients with recurrent optic pathway and hypothalamic low-grade gliomas.[41]

Six of 25 patients (24%) had a partial response, and an additional 14 of 25 patients (56%) had stable disease.

The 2-year PFS rate was 78%.

Of the 19 patients evaluable for visual acuity, 4 had improvements in visual acuity, with an additional 13 having stable findings.

In 2024, the FDA granted accelerated approval to tovorafenib (a type 2 RAF inhibitor) for the treatment of patients aged 6 months or older with relapsed or refractory low-grade glioma harboring a BRAF fusion or rearrangement or BRAF V600 variant. Approval was based on the results of a study of 137 patients (77 patients in the primary cohort [arm 1] and 60 patients in an extension cohort [arm 2]) who were treated with tovorafenib. The study was designed using Response Assessment in Neuro-Oncology High-Grade Glioma (RANO-HGG) criteria, which defines response as the reduction in the T1-Gd positive measurements.[42]

Sources: 42

In 2024, the FDA granted accelerated approval to tovorafenib (a type 2 RAF inhibitor) for the treatment of patients aged 6 months or older with relapsed or refractory low-grade glioma harboring a BRAF fusion or rearrangement or BRAF V600 variant. Approval was based on the results of a study of 137 patients (77 patients in the primary cohort [arm 1] and 60 patients in an extension cohort [arm 2]) who were treated with tovorafenib. The study was designed using Response Assessment in Neuro-Oncology High-Grade Glioma (RANO-HGG) criteria, which defines response as the reduction in the T1-Gd positive measurements.[42]

Using the RANO-HGG criteria, the overall response rate (ORR) was 67% for patients in arm 1, with a median duration of response (DOR) of 16.6 months.

When the data was analyzed using Response Assessment in Pediatric Neuro-Oncology (RAPNO) criteria, which defines response as the reduction in the T2/FLAIR signal, the ORR was 51%, with a median DOR of 13.8 months.

Health professional · Treatment of Progressive/Recurrent Circumscribed Astrocytic Gliomas, Pediatric-Type Diffuse Low-Grade Gliomas, and Glioneuronal/Neuronal Tumors

Treatment Options Under Clinical Evaluation

Source: Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 14, 2025. Captured 2026-09-09.

Early-phase therapeutic trials may be available for selected patients. These trials may be available via the COG, the Pediatric Brain Tumor Consortium, or other entities. Information about NCI-supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: COG · Pediatric Brain Tumor Consortium · NCI website · ClinicalTrials.gov website

Health professional

Treatment of Pediatric-Type Diffuse High-Grade Gliomas

Source: Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 14, 2025. Captured 2026-09-09.

To determine and implement optimal management, treatment is best guided by a multidisciplinary team of specialists experienced in treating pediatric patients with brain tumors.

The outcome for pediatric patients with the most common types of high-grade glioma (i.e., diffuse midline glioma, H3 K27-altered and diffuse pediatric-type high-grade glioma, H3-wild type and IDH-wild type) remains dismal.[1] In contrast, the prognosis for children with infant-type hemispheric glioma is relatively favorable.[2,3]

Sources: 1 · 2 · 3

Maximal safe surgical resection can be considered standard of care for all patients with pediatric-type diffuse high-grade glioma.[4]

Sources: 4

Standard adjuvant therapy for children with diffuse pediatric-type high-grade glioma, H3-wild type and IDH-wild type, includes radiation therapy and alkylator chemotherapy.[5-7]

Sources: 5 · 7

For children with diffuse midline glioma, H3 K27-altered (the most common subtype), including those with diffuse intrinsic pontine glioma (DIPG), adjuvant radiation therapy alone can be considered standard of care given the apparent lack of benefit of chemotherapy.[8,9]

Sources: 8 · 9

Standard treatment options for newly diagnosed pediatric-type diffuse high-grade gliomas include the following:

Surgery.

Sources: Surgery

Adjuvant therapy.

Sources: Adjuvant therapy

Adjuvant therapy.

Radiation therapy.

Sources: Radiation therapy

Chemotherapy.

Sources: Chemotherapy

Targeted therapy.

Sources: Targeted therapy

Immunotherapy.

Sources: Immunotherapy

Health professional · Treatment of Pediatric-Type Diffuse High-Grade Gliomas

Surgery

Source: Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 14, 2025. Captured 2026-09-09.

The extent of tumor resection at initial diagnosis is positively associated with survival. Therefore, maximal safe resection is recommended for children with nonpontine tumors.[4,10,11]

Sources: 4 · 10 · 11

For children with diffuse midline glioma in the pons (DIPG), histological confirmation is increasingly obtained for both entry into research studies and molecular characterization of the tumor.[12] New approaches with stereotactic needle biopsy may make biopsy safer.[13-16] Given the technical challenges of pontine biopsies, the procedure is best undertaken by an experienced pediatric neurosurgeon to minimize the risk of irreversible neurological complications.[13-17] Biopsy is recommended for pontine tumors when the diagnosis is uncertain based on imaging findings.

Sources: 12 · 13 · 16 · 13 · 17

Health professional · Treatment of Pediatric-Type Diffuse High-Grade Gliomas

Adjuvant Therapy

Source: Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 14, 2025. Captured 2026-09-09.

Health professional · Treatment of Pediatric-Type Diffuse High-Grade Gliomas / Adjuvant Therapy

Radiation therapy

Source: Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 14, 2025. Captured 2026-09-09.

For patients with diffuse midline glioma, H3 K27-altered and diffuse pediatric-type high-grade glioma, H3-wild type and IDH-wild type, focal radiation therapy is routinely administered to a field that widely encompasses the entire tumor. The radiation therapy dose to the tumor bed is usually at least 54 Gy. Despite such therapy, the prognosis is dismal. Similarly poor survival is seen in children with spinal cord primary tumors and children with thalamic high-grade gliomas (i.e., diffuse midline gliomas, H3 K27M-altered tumors) treated with radiation therapy.[18,19]; [20,21][Level of evidence C1]

Sources: 18 · 19 · 20 · 21 · Level of evidence C1

Standard treatment for children with diffuse midline gliomas centered in the pons is radiation therapy to the involved site. The conventional dose of radiation ranges between 54 Gy and 60 Gy, given locally to the primary tumor site in single daily fractions. Such treatment will result in transient benefit for most patients, but more than 90% of patients will die within 18 months of diagnosis.[22]

Sources: 22

Radiation-induced changes may occur a few months after the completion of radiation therapy and may mimic tumor progression. When considering the efficacy of additional treatment, care needs to be taken to separate radiation-induced change from progressive disease.[23]

Sources: 23

Research studies that evaluated the efficacy of hyperfractionated and hypofractionated radiation therapy and radiosensitizers have not demonstrated improved outcomes using these radiation techniques.

Hyperfractionated (twice daily) radiation therapy. Studies using doses as high as 78 Gy have been completed. Evidence demonstrates that these increased radiation therapy doses do not improve the duration or rate of survival for patients with DIPGs, whether given alone [24,25] or in combination with chemotherapy, and they were associated with increased toxicity at the highest dose levels.[26]

Sources: 24 · 25 · 26

Hypofractionated radiation therapy. This technique results in survival rates comparable with conventional fractionated radiation therapy techniques, possibly with less treatment burden.[27]; [28][Level of evidence A1]; [22,29][Level of evidence B4] One randomized study compared three radiation therapy fractions (39 Gy in 13 fractions; 45 Gy in 15 fractions; and 54 Gy in 30 fractions). The study concluded that the higher hypofractionated regimen was inferior, possibly due to increased toxicity.[30]

Sources: 27 · 28 · Level of evidence A1 · 22 · 29 · Level of evidence B4 · 30

Radiosensitizers. Studies evaluating the efficacy of various radiosensitizers as a means for enhancing the therapeutic effect of radiation therapy have been completed but have failed to show any significant improvement in outcome.[25,26,31-34]

Sources: 25 · 26 · 31 · 34

Health professional · Treatment of Pediatric-Type Diffuse High-Grade Gliomas / Adjuvant Therapy

Chemotherapy

Source: Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 14, 2025. Captured 2026-09-09.

For patients with diffuse pediatric-type high-grade glioma, H3-wild type and IDH-wild type, the benefit from radiation therapy with adjuvant chemotherapy compared with radiation therapy alone has not been formally proven in a randomized prospective trial. However, the aggregate data from numerous nonrandomized prospective clinical trials for children with high-grade gliomas suggest a benefit from alkylating chemotherapy, similar to adults with primary glioblastoma. Therefore, adjuvant therapy with a combination of radiation therapy and alkylating chemotherapy can be considered standard of care. Commonly used chemotherapy regimens include temozolomide alone or in combination with lomustine.[5,6]

Sources: 5 · 6

Prospective, randomized clinical trials in adults with primary glioblastoma have established MGMT promoter hypermethylation as an independent prognostic biomarker regardless of therapy, as well as a predictive biomarker for benefit from temozolomide.[35,36] However, in children with diffuse pediatric-type high-grade glioma, H3-wild type and IDH-wild type, MGMT promoter methylation status is not prognostic,[8,37] and its predictive value for benefit from alkylator chemotherapy is unknown given the lack of applicable randomized data.

Sources: 35 · 36 · 8 · 37

In a prospective randomized trial, the use of adjuvant bevacizumab after radiation therapy did not prolong overall survival (OS) or progression-free survival (PFS) in pediatric patients with newly diagnosed high-grade gliomas.[7]

Sources: 7

No chemotherapy (including neoadjuvant, concurrent, postradiation chemotherapy) or immunotherapy strategy, when added to radiation therapy, has led to long-term survival for children with DIPGs.[38-40]; [41][Level of evidence B4] This includes therapy using high-dose, marrow-ablative chemotherapy with autologous hematopoietic stem cell rescue, which has been shown to be ineffective in extending survival.[42] However, similar to the treatment of other brain tumors, radiation therapy is generally omitted for infants with DIPGs, and chemotherapy-only approaches are used. Published data supporting the utility of this approach are lacking.

Sources: 38 · 40 · 41 · Level of evidence B4 · 42

Children with infant-type hemispheric gliomas have been categorized into three groups.[43] Group 1 tumors include high-grade gliomas that are hemispheric and receptor tyrosine kinase (RTK) driven, including ALK, NTRK, ROS1, and MET gene fusions. Previously, infants with such tumors were treated with adjuvant multiagent chemotherapy instead of radiation therapy, with relatively favorable outcomes.[9,44]

Sources: 43 · 9 · 44

Health professional · Treatment of Pediatric-Type Diffuse High-Grade Gliomas

Targeted Therapy

Source: Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 14, 2025. Captured 2026-09-09.

Therapeutically targetable somatic BRAF V600E variants are present in a small subset of patients with pediatric-type diffuse high-grade gliomas. Data from a nonrandomized retrospective study suggest that up-front inclusion of BRAF and/or MEK inhibitor therapy in place of chemotherapy may result in improved survival.[45][Level of evidence C2]

Sources: 45 · Level of evidence C2

There is evidence that infants with group 1 hemispheric high-grade gliomas that have specific RTK-driven gene fusions are responsive to RTK-targeted therapeutics.[43,46] A subset analysis included 33 patients with NTRK fusion–positive central nervous system tumors who were treated with larotrectinib (included in two larger trials that enrolled children and adults with solid tumors and NTRK fusions).[47] The objective response rate was 30%, and 82% of patients with measurable disease had tumor shrinkage. The 12-month duration of response rate was 75%, the PFS rate was 56%, and the OS rate was 85%.[47] The role of RTK inhibitors in the up-front treatment of infants with pediatric-type high-grade glioma remains under study.

Sources: 43 · 46 · 47 · 47

Health professional · Treatment of Pediatric-Type Diffuse High-Grade Gliomas

Immunotherapy

Source: Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 14, 2025. Captured 2026-09-09.

Children with inheritable biallelic mismatch repair deficiency have a very high mutational burden and neoantigen expression. These patients are at risk of developing a variety of cancers, including hematologic malignancies, gastrointestinal cancers, and high-grade gliomas. The high variant and neoantigen load have been associated with responsiveness to immune checkpoint inhibition. Early case reports have demonstrated clinical imaging responses in children who are treated with an anti-programmed death-1 inhibitor.[48]

Sources: 48

Health professional · Treatment of Pediatric-Type Diffuse High-Grade Gliomas

Treatment Options Under Clinical Evaluation

Source: Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 14, 2025. Captured 2026-09-09.

Therapeutic clinical trials may be available for selected patients. These trials may be available via the Children's Oncology Group (COG), the Pediatric Brain Tumor Consortium, or other entities. Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: Children's Oncology Group (COG) · Pediatric Brain Tumor Consortium · NCI website · ClinicalTrials.gov website

Health professional

Treatment of Recurrent Pediatric-Type Diffuse High-Grade Gliomas

Source: Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 14, 2025. Captured 2026-09-09.

To determine and implement optimal management, treatment is best guided by a multidisciplinary team of specialists experienced in treating pediatric patients with brain tumors.

Treatment options for recurrent pediatric-type diffuse high-grade gliomas include the following:

Second surgery.

Sources: Second surgery

Radiation therapy.

Sources: Radiation therapy

Targeted therapy.

Sources: Targeted therapy

Immunotherapy.

Sources: Immunotherapy

Health professional · Treatment of Recurrent Pediatric-Type Diffuse High-Grade Gliomas

Second Surgery

Source: Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 14, 2025. Captured 2026-09-09.

The use of surgical intervention must be individualized based on the following:

Initial tumor type.

Length of time between initial treatment and the reappearance of the mass lesion.

Location of the recurrent tumor.

Consideration of therapeutics based on the requirement for fresh tumor tissue or to deliver therapy to the operative bed.

In most cases of diffuse midline gliomas centered in the pons (diffuse intrinsic pontine glioma [DIPG]), biopsy at the time of clinical or radiological progression is neither necessary nor recommended. Biopsy may be considered for confirmation of relapse when treatment-related brain stem damage, which may be clinically indistinguishable from tumor recurrence, is in the differential diagnosis. Other tests, including positron emission tomography, magnetic resonance spectroscopy, and single-photon emission computed tomography, are not reliable in distinguishing necrosis from tumor recurrence in previously irradiated patients with DIPG.

Health professional · Treatment of Recurrent Pediatric-Type Diffuse High-Grade Gliomas

Radiation Therapy

Source: Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 14, 2025. Captured 2026-09-09.

Radiation therapy is appropriate for patients who have not previously been irradiated. Radiation doses and volumes are similar to those used for newly diagnosed patients. Generally, this is limited to young children initially treated with radiation-avoiding strategies.

For previously irradiated patients with non–brain stem pediatric-type high-grade gliomas, reirradiation has been used, although the data demonstrating benefit are sparse. Stereotactic radiosurgery (SRS) or stereotactic radiation therapy (SRT) techniques using either hypofractionated radiation therapy or standard fraction sizes may be considered. For small volume distinct lesions, SRS allows for maximum sparing of normal tissues. For more infiltrative lesions, fractionated radiation therapy may better spare normal tissues.[1]

Sources: Stereotactic radiosurgery (SRS) · stereotactic radiation therapy (SRT) · 1

For patients with DIPG, reirradiation has been shown to prolong survival and can be considered at progression in children who have had an initial response to radiation therapy.[2,3] In a phase I/II study of 12 patients treated at three dose levels (24 Gy/12 fractions, 26.5 Gy/12 fractions, or 30.8 Gy/14 fractions), almost all patients improved. Clinical utility analysis showed that the 24-Gy regimen was preferable.[4] A recent survey confirms the effective use of even lower doses (e.g., 12 Gy fractionated). These doses are beneficial, and they allow for additional radiation therapy courses.[5]

Sources: 2 · 3 · 4 · 5

Health professional · Treatment of Recurrent Pediatric-Type Diffuse High-Grade Gliomas

Targeted Therapy

Source: Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 14, 2025. Captured 2026-09-09.

Somatic BRAF V600E variants are present in a small subset of patients. While many of these tumors are responsive to BRAF and/or MEK inhibitors, responses in the recurrent setting are typically not sustained long term. A median progression-free survival of approximately 3 months was reported in one retrospective series.[6] In a multicenter, open-label, single-arm, phase II trial that evaluated dabrafenib plus trametinib, 15 of 45 adult patients with BRAF V600E variants and high-grade gliomas had an objective response. There were three complete responses and 12 partial responses, with a median overall survival of 17.6 months.[7]

Sources: 6 · 7

The U.S. Food and Drug Administration (FDA) approved the combination of dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) for adult and pediatric patients aged 1 year and older with unresectable or metastatic solid tumors with BRAF V600E variants who have progressed following prior treatment and have no satisfactory alternative treatment options.[8,9] This approval includes pediatric patients aged 1 year and older with BRAF V600E variants and high-grade gliomas. The approval for this patient population was based on the results described below:[8-10]

Sources: 8 · 9 · 8 · 10

The dabrafenib-plus-trametinib combination was studied in 41 pediatric patients with relapsed or progressive high-grade gliomas.

The median age of enrolled patients was 13 years.

The objective response rate was 56% (95% confidence interval [CI], 39.7%–71.5%).

For the 23 patients who achieved objective responses, 48% of patients had a duration of response of 12 months and longer and 22% of patients had a duration of response of 24 months or longer.

Activating gene fusions (ALK, NTRK1, NTRK2, NTRK3, ROS1, and MET) are characteristic of infant-type diffuse gliomas.[11,12] Data from case reports and recent prospective clinical trials suggest that these tumors are highly responsive to targeted therapies.[13]

Sources: 11 · 12 · 13

Tumor sample sequencing was done in pediatric (n = 54) and young adult patients (n = 15) with recurrent or refractory high-grade gliomas who were enrolled in the National Cancer Institute (NCI)–Children's Oncology Group (COG) Pediatric MATCH trial. The test revealed genomic alterations that were considered actionable for treatment on MATCH study arms in 36 of 69 tumors (52.2%).[14] Alterations in MAPK pathway genes were detected in 17 of 69 tumors (24.6%), most frequently BRAF V600E variants or fusions (n = 11, 15.9%). FGFR1 variants or fusions were identified in 6 of 69 tumors (8.7%).

Sources: 14

Health professional · Treatment of Recurrent Pediatric-Type Diffuse High-Grade Gliomas

Immunotherapy

Source: Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 14, 2025. Captured 2026-09-09.

Numerous studies are investigating a variety of immunotherapy strategies, including checkpoint inhibitors,[15] oncolytic viruses, chimeric antigen receptor (CAR) T cells, and other immune-modulating strategies. GD2-CAR T cells were administered intravenously and intraventricularly in a small study of 11 patients to treat H3 K27M-altered diffuse midline gliomas. The paper describes a reduction in tumor volume for some patients. However, in a number of cases, the contribution of the CAR T-cell therapy to the tumor reduction is difficult to separate from the effects of the antecedent radiation therapy treatment. This treatment required substantial supportive care, including early placement of an Ommaya reservoir to manage central nervous system complications, which included both immune effector cell acute neurotoxicity syndrome (ICANS) and tumor inflammation–associated neurotoxicity.[16]

Sources: 15 · 16

Health professional · Treatment of Recurrent Pediatric-Type Diffuse High-Grade Gliomas

Treatment Options Under Clinical Evaluation

Source: Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 14, 2025. Captured 2026-09-09.

The role of immune checkpoint inhibition in the treatment of children with recurrent high-grade astrocytoma is currently under study. Children with biallelic mismatch repair deficiency have a very high mutational burden and neoantigen expression and are at risk of developing a variety of cancers, including hematologic malignancies, gastrointestinal cancers, and brain tumors. The high variant and neoantigen load has been correlated with improved response to immune checkpoint inhibition. Early case reports have demonstrated clinical and radiographic responses in children who are treated with an anti–programmed death-1 inhibitor.[17]

Sources: 17

Patients for whom initial treatment fails may benefit from additional treatment, including entry into clinical trials of novel therapeutic approaches.[18] Early-phase therapeutic trials may be available for selected patients. These trials may be available via the COG, the Pediatric Brain Tumor Consortium, or other entities. Information about NCI-supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: 18 · COG · Pediatric Brain Tumor Consortium · NCI website · ClinicalTrials.gov website

For patients

Types of treatment for childhood glioma (including astrocytoma)

Source: Childhood Glioma (Including Astrocytoma), National Cancer Institute.

Source updated: May 10, 2024. Captured 2026-09-09.

There are different types of treatment for children and adolescents with glioma. You and your child's cancer care team will work together to decide treatment. Many factors will be considered, such as your child's overall health, the tumor grade, and whether the cancer is newly diagnosed or has come back.

A pediatric oncologist, a doctor who specializes in treating children with cancer, will oversee treatment. The pediatric oncologist works with other health care providers who are experts in treating children with brain tumors and who specialize in certain areas of medicine. Other specialists may include:

pediatrician

Sources: pediatrician

pediatric neurosurgeon

Sources: pediatric · neurosurgeon

neurologist

Sources: neurologist

neuropathologist

Sources: neuropathologist

neuroradiologist

Sources: neuroradiologist

rehabilitation specialist

Sources: rehabilitation specialist

radiation oncologist

Sources: radiation oncologist

endocrinologist

Sources: endocrinologist

psychologist

Sources: psychologist

social worker

Sources: social worker

child-life specialist

Sources: child-life specialist

fertility specialist

Sources: fertility specialist

Your child's treatment plan will include information about the cancer, the goals of treatment, treatment options, and the possible side effects. It will be helpful to talk with your child's cancer care team before treatment begins about what to expect. For help every step of the way, see our downloadable booklet, Children with Cancer: A Guide for Parents.

Sources: Children with Cancer: A Guide for Parents

For patients · Types of treatment for childhood glioma (including astrocytoma)

Surgery

Source: Childhood Glioma (Including Astrocytoma), National Cancer Institute.

Source updated: May 10, 2024. Captured 2026-09-09.

Surgery is used to diagnose and treat childhood gliomas, as discussed in the Tests to diagnose childhood glioma (including astrocytoma) section of this summary. After surgery, an MRI (magnetic resonance imaging) is done to see if any cancer cells remain. If cancer cells are found, further treatment depends on:

Sources: Tests to diagnose childhood glioma (including astrocytoma)

where the remaining cancer cells are

the grade of the tumor

your child's age

After the doctor removes all the cancer that can be seen at the time of the surgery, some children may be given chemotherapy or radiation therapy to kill any cancer cells that are left. Treatment given after the surgery, to lower the risk that the cancer will come back, is called adjuvant therapy.

Sources: chemotherapy · radiation therapy · adjuvant therapy

Sometimes children with a glioma have increased fluid around the brain or spinal cord. They may need surgery to place a shunt (long, thin tube) in a ventricle (fluid-filled space) of the brain and thread it under the skin to another part of the body, usually the abdomen. The shunt carries extra fluid away from the brain so it may be absorbed elsewhere in the body. This decreases the fluid and pressure on the brain or spinal cord. This process is called a CSF shunt.

For patients · Types of treatment for childhood glioma (including astrocytoma)

Observation

Source: Childhood Glioma (Including Astrocytoma), National Cancer Institute.

Source updated: May 10, 2024. Captured 2026-09-09.

Observation is closely monitoring a person's condition without giving any treatment or additional treatment until signs or symptoms appear or change. Observation may be used:

if your child has no symptoms, such as children with neurofibromatosis type 1 (NF1)

Sources: neurofibromatosis type 1 (NF1)

if your child's tumor is small and is found when a different health problem is being diagnosed or treated

after the tumor is removed by surgery until signs or symptoms appear or change

For patients · Types of treatment for childhood glioma (including astrocytoma)

Chemotherapy

Source: Childhood Glioma (Including Astrocytoma), National Cancer Institute.

Source updated: May 10, 2024. Captured 2026-09-09.

Chemotherapy (also called chemo) uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Chemotherapy may be given alone or with other types of treatment, such as radiation therapy.

To treat a glioma, chemotherapy is taken by mouth or injected into a vein. When given this way, the drugs enter the bloodstream and can reach cancer cells throughout the body. Chemotherapy that may be used includes:

Sources: injected

carboplatin

Sources: carboplatin

irinotecan

Sources: irinotecan

lenalidomide

Sources: lenalidomide

lomustine

Sources: lomustine

procarbazine

Sources: procarbazine

temozolomide

Sources: temozolomide

thioguanine

Sources: thioguanine

vinblastine

Sources: vinblastine

vincristine

Sources: vincristine

Combinations of these drugs may be used. Other chemotherapy drugs not listed here may also be used.

Learn more about Chemotherapy to Treat Cancer.

Sources: Chemotherapy to Treat Cancer

For patients · Types of treatment for childhood glioma (including astrocytoma)

Radiation therapy

Source: Childhood Glioma (Including Astrocytoma), National Cancer Institute.

Source updated: May 10, 2024. Captured 2026-09-09.

Radiation therapy uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. Glioma may be treated with external beam radiation therapy. This type of treatment uses a machine outside the body to send radiation toward the area of the body with cancer. Radiation therapy may be given alone or with other treatments, such as chemotherapy.

Sources: x-rays · radiation

Certain ways of giving external beam radiation therapy can help keep radiation from damaging nearby healthy tissue. These types of radiation therapy include:

Conformal radiation therapy uses a computer to make a 3-dimensional (3-D) picture of the tumor and shapes the radiation beams to fit the tumor. This allows a high dose of radiation to reach the tumor and causes less damage to nearby healthy tissue.

Sources: Conformal radiation therapy · 3-dimensional

Intensity-modulated radiation therapy (IMRT) uses a computer to make 3-D pictures of the size and shape of the tumor. Thin beams of radiation of different intensities (strengths) are aimed at the tumor from many angles.

Sources: Intensity-modulated radiation therapy

Stereotactic radiation therapy uses a machine that aims radiation directly at the tumor causing less damage to nearby healthy tissue. The total dose of radiation is divided into several smaller doses given over several days. A rigid head frame is attached to the skull to keep the head still during the radiation treatment. This procedure is also called stereotactic radiosurgery and stereotaxic radiation therapy.

Sources: Stereotactic radiation therapy · skull

Proton beam radiation therapy is a type of high-energy, external radiation therapy that uses streams of protons (tiny particles with a positive charge) to kill tumor cells. This type of treatment can lower the amount of radiation damage to healthy tissue near a tumor.

Sources: Proton beam radiation therapy · protons

The way radiation therapy is given depends on the type of tumor and where the tumor formed in the brain or spinal cord.

Radiation therapy to the brain can affect growth and development, especially in young children. For children younger than 3 years, chemotherapy may be given instead, to delay or reduce the need for radiation therapy. Radiation therapy may also be delayed for patients with NF1 because they may be at increased risk for a second cancer.

To learn more, see External Beam Radiation Therapy for Cancer and Radiation Therapy Side Effects.

Sources: External Beam Radiation Therapy for Cancer · Radiation Therapy Side Effects

For patients · Types of treatment for childhood glioma (including astrocytoma)

Targeted therapy

Source: Childhood Glioma (Including Astrocytoma), National Cancer Institute.

Source updated: May 10, 2024. Captured 2026-09-09.

Targeted therapy uses drugs or other substances to block the action of specific enzymes, proteins, or other molecules involved in the growth and spread of cancer cells.

Targeted therapies that may be used or are being studied to treat glioma include:

bevacizumab

Sources: bevacizumab

dabrafenib

Sources: dabrafenib

everolimus

Sources: everolimus

larotrectinib

Sources: larotrectinib

selumetinib

Sources: selumetinib

sirolimus

Sources: sirolimus

trametinib

Sources: trametinib

Learn more about Targeted Therapy to Treat Cancer.

Sources: Targeted Therapy to Treat Cancer

For patients · Types of treatment for childhood glioma (including astrocytoma)

Clinical trials

Source: Childhood Glioma (Including Astrocytoma), National Cancer Institute.

Source updated: May 10, 2024. Captured 2026-09-09.

A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for people with cancer. Because cancer in children is rare, taking part in a clinical trial should be considered.

Use our clinical trials search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. Some clinical trials are open only to patients who have not started treatment. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: clinical trials search · ClinicalTrials.gov

To learn more, see Clinical Trials Information for Patients and Caregivers.

Sources: Clinical Trials Information for Patients and Caregivers

For patients · Types of treatment for childhood glioma (including astrocytoma) / Clinical trials

Immunotherapy

Source: Childhood Glioma (Including Astrocytoma), National Cancer Institute.

Source updated: May 10, 2024. Captured 2026-09-09.

Immunotherapy helps a person's immune system fight cancer.

The following treatments are being studied to treat glioma:

oncolytic virus therapy

Sources: oncolytic virus therapy

chimeric antigen receptor (CAR) T-cell therapy

Sources: chimeric antigen receptor (CAR) T-cell therapy

drugs that block the activity of PD-1

Sources: PD-1

Learn more about how immunotherapy works against cancer, how it is given, and possible side effects, and more in Immunotherapy to Treat Cancer.

Sources: Immunotherapy to Treat Cancer

For patients

Treatment of newly diagnosed childhood low-grade glioma, astrocytoma, neuronal, and glioneuronal tumors

Source: Childhood Glioma (Including Astrocytoma), National Cancer Institute.

Source updated: May 10, 2024. Captured 2026-09-09.

Children with neurofibromatosis type 1 and a central nervous system tumor, children with an optic pathway glioma, or children who had a tumor found when getting a scan for another health problem may be observed (closely watched). These children may not receive treatment until signs or symptoms appear or change or the tumor grows.

Sources: neurofibromatosis type 1 · central nervous system tumor · optic pathway glioma

Children with tuberous sclerosis may develop low-grade tumors in the brain called subependymal giant cell astrocytoma (SEGAs). Targeted therapy with everolimus or sirolimus may be used instead of surgery, to shrink the tumors.

Sources: subependymal giant cell astrocytoma (SEGAs) · Targeted therapy · everolimus · sirolimus

Children diagnosed with low-grade glioma are treated based on where the tumor is located. The first treatment is usually surgery. An MRI is done after surgery to see if any tumor remains. If the tumor was completely removed by surgery, more treatment may not be needed and the child is closely observed.

If there is tumor remaining after surgery, treatment may include:

observation for children who had surgery to remove part of the tumor and the tumor is expected to regrow slowly

combination chemotherapy with or without radiation therapy

Sources: combination chemotherapy

radiation therapy, which may include conformal radiation therapy, intensity-modulated radiation therapy, proton beam radiation therapy, or stereotactic radiation therapy, may be used if the tumor does not respond to chemotherapy or when the tumor begins to grow again

Sources: conformal radiation therapy · intensity-modulated radiation therapy · proton beam radiation therapy · stereotactic radiation therapy

targeted therapy (trametinib and dabrafenib)

Sources: trametinib · dabrafenib

a clinical trial of targeted therapy (selumetinib) with or without chemotherapy

Sources: selumetinib

To learn more about these treatments, see Types of treatment for childhood glioma (including astrocytoma).

Sources: Types of treatment for childhood glioma (including astrocytoma)

For patients

Treatment of progressive or recurrent childhood low-grade glioma, astrocytoma, neuronal, or glioneuronal tumors

Source: Childhood Glioma (Including Astrocytoma), National Cancer Institute.

Source updated: May 10, 2024. Captured 2026-09-09.

Childhood glioma, astrocytoma, glioneuronal, and neuronal tumors can be progressive or recurrent. They most often come back in the same area but can spread to other areas in the brain. Before more cancer treatment is given, imaging tests, biopsy, or surgery are done to find out if there is cancer, how much there is, and the grade.

Sources: progressive · recurrent

Treatment of progressive or recurrent childhood low-grade glioma, astrocytoma, glioneuronal, and neuronal tumors may include:

Sources: low-grade · glioma · astrocytoma

a second surgery to remove the tumor

radiation therapy (including conformal radiation therapy), if radiation therapy was not used when the tumor was first diagnosed

chemotherapy, if the tumor progressed or recurred where it cannot be removed by surgery

targeted therapy (bevacizumab) with or without chemotherapy

Sources: bevacizumab

targeted therapy (everolimus or sirolimus)

Sources: everolimus · sirolimus

targeted therapy (dabrafenib and trametinib)

Sources: dabrafenib · trametinib

To learn more about these treatments, see Types of treatment for childhood glioma (including astrocytoma).

Sources: Types of treatment for childhood glioma (including astrocytoma)

For patients

Treatment of childhood high-grade gliomas

Source: Childhood Glioma (Including Astrocytoma), National Cancer Institute.

Source updated: May 10, 2024. Captured 2026-09-09.

Treatment of newly diagnosed childhood high-grade glioma may include:

Sources: high-grade · glioma

surgery to remove the tumor

radiation therapy with or without chemotherapy

a clinical trial of targeted therapy with a combination of dabrafenib and trametinib after radiation therapy to treat newly diagnosed high-grade glioma that has mutations in the BRAF gene

Sources: dabrafenib · trametinib · mutations

a clinical trial of immunotherapy

To learn more about these treatments, see Types of treatment for childhood glioma (including astrocytoma).

Sources: Types of treatment for childhood glioma (including astrocytoma)

For patients

Treatment of recurrent childhood high-grade gliomas

Source: Childhood Glioma (Including Astrocytoma), National Cancer Institute.

Source updated: May 10, 2024. Captured 2026-09-09.

Treatment of recurrent childhood high-grade glioma may include:

Sources: recurrent · high-grade · glioma

second surgery depending on tumor type, location, and length of time between treatment and recurrence

radiation therapy

targeted therapy (dabrafenib and trametinib)

Sources: dabrafenib · trametinib

a clinical trial of targeted therapy

a clinical trial of immunotherapy

Sources: immunotherapy

To learn more about these treatments, see Types of treatment for childhood glioma (including astrocytoma).

Sources: Types of treatment for childhood glioma (including astrocytoma)

For patients

Side effects from the tumor and treatment

Source: Childhood Glioma (Including Astrocytoma), National Cancer Institute.

Source updated: May 10, 2024. Captured 2026-09-09.

The signs or symptoms caused by the tumor may begin before diagnosis and continue for months or years. It is important to talk with your child's doctors about signs or symptoms caused by the tumor that may continue after treatment.

To learn more about side effects that begin during treatment for cancer, visit Side Effects.

Sources: side effects · Side Effects

Problems from cancer treatment that begin 6 months or later after treatment and continue for months or years are called late effects. Late effects of cancer treatment may include:

physical problems that affect:

physical problems that affect:

vision, including blindness

blood vessels

hormone levels

Sources: hormone

changes in mood, feelings, thinking, learning, or memory

second cancers (new types of cancer)

Some late effects may be treated or controlled. It is important to talk with your child's doctors about the effects cancer treatment can have on your child. To learn more, see Late Effects of Treatment for Childhood Cancer.

Sources: Late Effects of Treatment for Childhood Cancer

For patients

Treatment of newly diagnosed childhood low-grade glioma, astrocytoma, neuronal, and glioneuronal tumors

Source: Childhood Glioma (Including Astrocytoma), National Cancer Institute.

Source updated: May 10, 2024. Captured 2026-09-09.

Children with neurofibromatosis type 1 and a central nervous system tumor, children with an optic pathway glioma, or children who had a tumor found when getting a scan for another health problem may be observed (closely watched). These children may not receive treatment until signs or symptoms appear or change or the tumor grows.

Sources: neurofibromatosis type 1 · central nervous system tumor · optic pathway glioma

Children with tuberous sclerosis may develop low-grade tumors in the brain called subependymal giant cell astrocytoma (SEGAs). Targeted therapy with everolimus or sirolimus may be used instead of surgery, to shrink the tumors.

Sources: subependymal giant cell astrocytoma (SEGAs) · Targeted therapy · everolimus · sirolimus

Children diagnosed with low-grade glioma are treated based on where the tumor is located. The first treatment is usually surgery. An MRI is done after surgery to see if any tumor remains. If the tumor was completely removed by surgery, more treatment may not be needed and the child is closely observed.

If there is tumor remaining after surgery, treatment may include:

observation for children who had surgery to remove part of the tumor and the tumor is expected to regrow slowly

combination chemotherapy with or without radiation therapy

Sources: combination chemotherapy

radiation therapy, which may include conformal radiation therapy, intensity-modulated radiation therapy, proton beam radiation therapy, or stereotactic radiation therapy, may be used if the tumor does not respond to chemotherapy or when the tumor begins to grow again

Sources: conformal radiation therapy · intensity-modulated radiation therapy · proton beam radiation therapy · stereotactic radiation therapy

targeted therapy (trametinib and dabrafenib)

Sources: trametinib · dabrafenib

a clinical trial of targeted therapy (selumetinib) with or without chemotherapy

Sources: selumetinib

To learn more about these treatments, see Types of treatment for childhood glioma (including astrocytoma).

Sources: Types of treatment for childhood glioma (including astrocytoma)

For patients

Treatment of progressive or recurrent childhood low-grade glioma, astrocytoma, neuronal, or glioneuronal tumors

Source: Childhood Glioma (Including Astrocytoma), National Cancer Institute.

Source updated: May 10, 2024. Captured 2026-09-09.

Childhood glioma, astrocytoma, glioneuronal, and neuronal tumors can be progressive or recurrent. They most often come back in the same area but can spread to other areas in the brain. Before more cancer treatment is given, imaging tests, biopsy, or surgery are done to find out if there is cancer, how much there is, and the grade.

Sources: progressive · recurrent

Treatment of progressive or recurrent childhood low-grade glioma, astrocytoma, glioneuronal, and neuronal tumors may include:

Sources: low-grade · glioma · astrocytoma

a second surgery to remove the tumor

radiation therapy (including conformal radiation therapy), if radiation therapy was not used when the tumor was first diagnosed

chemotherapy, if the tumor progressed or recurred where it cannot be removed by surgery

targeted therapy (bevacizumab) with or without chemotherapy

Sources: bevacizumab

targeted therapy (everolimus or sirolimus)

Sources: everolimus · sirolimus

targeted therapy (dabrafenib and trametinib)

Sources: dabrafenib · trametinib

To learn more about these treatments, see Types of treatment for childhood glioma (including astrocytoma).

Sources: Types of treatment for childhood glioma (including astrocytoma)

Studies

Combination Chemotherapy in Treating Children With Progressive Brain Tumors

NCT00002944 · COMPLETED · phase3

Brain Tumors, Central Nervous System Tumors

ClinicalTrials.gov record

Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy

NCT00030108 · COMPLETED · phase1

Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Leukemia, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma,...

ClinicalTrials.gov record

Radiation Therapy or Combination Chemotherapy in Treating Patients With Clinically or Radiologically Progressive Low-Grade Gliomas

NCT00276640 · COMPLETED · na

Primary Central Nervous System Neoplasms

ClinicalTrials.gov record

Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

NCT01089101 · ACTIVE NOT RECRUITING · phase1, phase2

Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma, Recurrent Neurofibromatosis Type 1, Recurrent Visual Pathway Glioma, Refractory Neurofibromatosis Type 1,...

ClinicalTrials.gov record

Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

NCT02255461 · TERMINATED · phase1

Childhood Choroid Plexus Tumor, Childhood Ependymoblastoma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral...

ClinicalTrials.gov record

Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

NCT02415153 · COMPLETED · phase1

Neurofibromatosis Type 1, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Visual Pathway Glioma, Recurrent Primary Central Nervous System Neoplasm, Refractory...

ClinicalTrials.gov record

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

NCT02684058 · COMPLETED · phase2

Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood, Anaplastic Oligodendroglioma, Glioblastoma, Pilocytic Astrocytoma, Giant Cell...

ClinicalTrials.gov record

Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors

NCT03245151 · COMPLETED · phase1, phase2

Recurrent and Refractory Solid Tumors

ClinicalTrials.gov record

A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma

NCT03871257 · ACTIVE NOT RECRUITING · phase3

Low Grade Glioma, Neurofibromatosis Type 1, Visual Pathway Glioma

ClinicalTrials.gov record

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

NCT04166409 · RECRUITING · phase3

Low Grade Astrocytoma, Low Grade Glioma, Metastatic Low Grade Astrocytoma, Metastatic Low Grade Glioma, WHO Grade 1 Glioma, WHO Grade 2 Glioma

ClinicalTrials.gov record

Antineoplaston Therapy in Treating Children With Brain Tumors

NCT00003458 · COMPLETED · phase2

Childhood Brain Tumors

ClinicalTrials.gov record

Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors

NCT00024258 · COMPLETED · phase2

Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Retinoblastoma,...

ClinicalTrials.gov record

Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT

NCT00084838 · COMPLETED · phase2

Central Nervous System Tumor, Pediatric

ClinicalTrials.gov record

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

NCT00357500 · COMPLETED · phase2

Central Nervous System Tumor, Pediatric, Leukemia, Lymphoma, Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific

ClinicalTrials.gov record

Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain

NCT00452868 · COMPLETED · early phase1

Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Long-term Effects Secondary to Cancer Therapy in Children, Neurotoxicity, Psychosocial Effects of Cancer...

ClinicalTrials.gov record

Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors

NCT00788125 · TERMINATED · phase1, phase2

Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Sarcoma,...

ClinicalTrials.gov record

Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors

NCT01100658 · TERMINATED · na

ALL, Childhood, Leukemia, Lymphoblastic, Leukemia, Lymphoblastic, Acute, Leukemia, Lymphoblastic, Acute, L1, Leukemia, Lymphoblastic, Acute, L2, Leukemia, Lymphoblastic, Acute,...

ClinicalTrials.gov record

Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy

NCT01346267 · COMPLETED · na

Central Nervous System Tumor, Pediatric, Chemotherapy-induced Nausea and Vomiting, Unspecified Childhood Solid Tumor, Protocol Specific

ClinicalTrials.gov record

Methylphenidate HCl or Modafinil in Treating Young Patients With Excessive Daytime Sleepiness After Cancer Therapy

NCT01348607 · TERMINATED · phase2

Central Nervous System Tumor, Pediatric, Fatigue, Specific Disorders of Sleep

ClinicalTrials.gov record

Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma

NCT01553149 · COMPLETED · phase2

Neurofibromatosis Type 1, Recurrent Childhood Pilocytic Astrocytoma, Recurrent Childhood Visual Pathway Glioma

ClinicalTrials.gov record

Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas

NCT02343224 · COMPLETED · phase2

Juvenile Pilocytic Astrocytomas, Optic Pathway Gliomas

ClinicalTrials.gov record

Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors

NCT02372409 · TERMINATED · phase2

Glioma, Pilocytic Astrocytoma, Anaplastic Astrocytoma, Glioblastoma, Mixed Oligoastrocytoma, Mixed Glioma, Oligodendroglioma, Optic Glioma, Astrocytoma

ClinicalTrials.gov record

Disease and treatment settings

Childhood Anaplastic Astrocytoma

Disease and treatment setting

Childhood Anaplastic Astrocytoma

Childhood Cerebellar Anaplastic Astrocytoma

Disease and treatment setting

Childhood Cerebellar Anaplastic Astrocytoma

Childhood Cerebellar Astrocytoma

Disease and treatment setting

Childhood Cerebellar Astrocytoma

Childhood Cerebral Astrocytoma

Disease and treatment setting

Childhood Cerebral Astrocytoma

Childhood Fibrillary Astrocytoma

Disease and treatment setting

Childhood Fibrillary Astrocytoma

Childhood Gemistocytic Astrocytoma

Disease and treatment setting

Childhood Gemistocytic Astrocytoma

Childhood Giant Cell Glioblastoma

Disease and treatment setting

Childhood Giant Cell Glioblastoma

Childhood Pilomyxoid Astrocytoma

Disease and treatment setting

Childhood Pilomyxoid Astrocytoma

Childhood Protoplasmic Astrocytoma

Disease and treatment setting

Childhood Protoplasmic Astrocytoma

Recurrent Childhood Anaplastic Astrocytoma

Disease and treatment setting

Recurrent Childhood Anaplastic Astrocytoma

Recurrent Childhood Diffuse Astrocytoma

Disease and treatment setting

Recurrent Childhood Diffuse Astrocytoma

Recurrent Childhood Glioblastoma

Disease and treatment setting

Recurrent Childhood Glioblastoma

Recurrent Childhood Pilomyxoid Astrocytoma

Disease and treatment setting

Recurrent Childhood Pilomyxoid Astrocytoma

Drug labels

OJEMDA

Label date 2025-09-02

OJEMDA is indicated for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. This indication is approved under...

DailyMed label